
According to reports from CNBC TV18, Shilpa Medicare delivered exceptional financial results for Q2 FY27, with consolidated net profit rising 79.5% year-on-year to ₹79 crore, compared with ₹44 crore in the corresponding quarter last year. Total income increased 45% to ₹538 crore in Q2 FY27, hitting a record high, compared with ₹372 crore a year ago, as reported in the company's exchange filing. EBITDA rose 37% YoY to ₹151 crore from ₹110 crore in the year-ago period, though EBITDA margin declined 200 basis points to 28% from 30% in the corresponding quarter last year. The company also disclosed that the exclusion of subsidiary FTF Pharma Private Limited from consolidation after September 8, 2026, due to the initiation of Corporate Insolvency Resolution Process (CIRP), resulted in lower reported consolidated revenue by ₹2.78 crore and PBT by ₹3.75 crore for the quarter.
As reported by CNBC TV18, the company's specialty contract development and manufacturing organisation (CDMO) business is set to benefit from commercial supplies to a European customer expected to commence in the second half of FY27, marking an upcoming revenue milestone. Shilpa Medicare reported a strong order book in its peptide segment, providing healthy revenue visibility for FY27. The company is expanding its peptide manufacturing capabilities, adding one of India's largest solid-phase synthesis capacities designed to cater to requirements across GLP-1, high-potency active pharmaceutical ingredients (HPAPI) and CDMO segments. The company's semaglutide drug master file (DMF) is ready for filing.
According to CNBC TV18, Shilpa Medicare has onboarded a new US customer and received initial orders, with execution expected to be completed by the second half of FY27. The company has also added a new customer from Japan, with commercial supplies expected to begin by the end of FY27. The company highlighted its expanded partnership with Orion Corporation, which extends their relationship into immuno-oncology through an exclusive arrangement for Shilpa Medicare's Nivolumab biosimilar in Europe. Under this arrangement, Shilpa Medicare will serve as the development and supply partner.
As reported by CNBC TV18, the API segment contributed 47% to revenue, delivering its highest-ever quarterly sales in Q2 FY27. The growth was driven by broad-based momentum across all three key verticals: API, Formulations, and Biologics. However, there was a divergence between absolute growth and margin efficiency, as while EBITDA increased by 37% in absolute terms, the EBITDA margin contracted by approximately 200 basis points, falling from 30% to 28%. Despite this, the adjusted ROCE improved to 18.2% in 1HFY27 from 17.4% in FY26, while Net Debt to EBITDA declined to 1.3x from 1.4x in FY26, indicating stronger capital efficiency and deleveraging supported by strong operating cash flows of ₹326 crore in the first half.